Back
Evolving Treatment Landscape in Relapsed and Refractory Multiple Myeloma
Explore evolving clinical considerations in relapsed and refractory multiple myeloma, drawing on recent clinical trial data, real-world evidence, and insights from major scientific meetings, including ASH 2025.
Evolving Treatment Landscape in Relapsed and Refractory Multiple Myeloma
Episodes
All
All
Explore how early-relapse multiple myeloma treatment shifts toward CAR T and bispecifics, weighing high-risk biology, kidney issues, logistics, and infection safety.
Experts weigh how to sequence myeloma therapies, highlighting where antibody-drug conjugates like belantamab fit when CAR-T or bispecific options aren’t feasible.
Early myeloma referral to academic centers helps patients access trials, avoid therapy pitfalls, and stay eligible for earlier CAR-T and bispecifics.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
4
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
5